Drug Discovery and Development: The Road from an Idea to Promoting Human Health

Author(s):  
Eugene H. Cordes

We are almost where we need to be to grasp the tales of drug discovery that make up the final seven chapters of this book. The three previous chapters have laid the necessary scientific foundation. Here is my take on what you still need to know to understand drug discovery and development: the process of getting from an idea to a product that meets a medical need—from the laboratory to the bedside. We begin with a look at the process from 35,000 feet. Realize one thing at the outset: there is more than one way of getting from an idea to approval of a new drug for use in human medicine. The process described in this chapter captures the essential features of getting this done. However, each drug discovery effort poses specific problems, and getting around them may have an effect on the actual process followed. Nonetheless, what is described here is well worth understanding. Imagine running a maze that may have more than two dimensions, a huge number of entry points, and a very small number of exits or perhaps no exit at all, depending on your entry point. Have a look at Figure 5.1 to get the idea. You can see the external features but have no clue what awaits you inside. You can wander in this maze for a long time without getting very far. This pretty well symbolizes what happens during a lot of drug discovery projects. In target-based drug discovery, described in the next section, each entry point in the maze corresponds to a molecule chosen as a starting place to begin work. Most of these entry points are dead ends. No matter what you do or how hard you try, the only exit from the maze is the place you entered—nothing gained. The journey may be long, there may be encouraging signs along the way, but at the end of the day, you are back where you started.

2020 ◽  
Author(s):  
Sanaa Bardaweel

Recently, an outbreak of fatal coronavirus, SARS-CoV-2, has emerged from China and is rapidly spreading worldwide. As the coronavirus pandemic rages, drug discovery and development become even more challenging. Drug repurposing of the antimalarial drug chloroquine and its hydroxylated form had demonstrated apparent effectiveness in the treatment of COVID-19 associated pneumonia in clinical trials. SARS-CoV-2 spike protein shares 31.9% sequence identity with the spike protein presents in the Middle East Respiratory Syndrome Corona Virus (MERS-CoV), which infects cells through the interaction of its spike protein with the DPP4 receptor found on macrophages. Sitagliptin, a DPP4 inhibitor, that is known for its antidiabetic, immunoregulatory, anti-inflammatory, and beneficial cardiometabolic effects has been shown to reverse macrophage responses in MERS-CoV infection and reduce CXCL10 chemokine production in AIDS patients. We suggest that Sitagliptin may be beneficial alternative for the treatment of COVID-19 disease especially in diabetic patients and patients with preexisting cardiovascular conditions who are already at higher risk of COVID-19 infection.


2020 ◽  
Vol 20 (10) ◽  
pp. 855-882
Author(s):  
Olivia Slater ◽  
Bethany Miller ◽  
Maria Kontoyianni

Drug discovery has focused on the paradigm “one drug, one target” for a long time. However, small molecules can act at multiple macromolecular targets, which serves as the basis for drug repurposing. In an effort to expand the target space, and given advances in X-ray crystallography, protein-protein interactions have become an emerging focus area of drug discovery enterprises. Proteins interact with other biomolecules and it is this intricate network of interactions that determines the behavior of the system and its biological processes. In this review, we briefly discuss networks in disease, followed by computational methods for protein-protein complex prediction. Computational methodologies and techniques employed towards objectives such as protein-protein docking, protein-protein interactions, and interface predictions are described extensively. Docking aims at producing a complex between proteins, while interface predictions identify a subset of residues on one protein that could interact with a partner, and protein-protein interaction sites address whether two proteins interact. In addition, approaches to predict hot spots and binding sites are presented along with a representative example of our internal project on the chemokine CXC receptor 3 B-isoform and predictive modeling with IP10 and PF4.


2011 ◽  
Vol 999 (999) ◽  
pp. 1-29
Author(s):  
Jeremy N. Burrows ◽  
Kelly Chibale ◽  
Timothy N.C. Wells

In an epoch when environmental issues make the headlines, this is a work that goes beyond the everyday. Ecologies as diverse as the Himalayas and the Indian Ocean coast, the Negev desert and the former military bases of Vietnam, or the Namib desert and the east African savannah all have in common a long-time human presence and the many ways people have modified nature. With research in six Asian and African countries, the authors come together to ask how and why human impacts on nature have grown in scale and pace from a long pre-history. The chapters in this volume illumine specific patterns and responses across time, going beyond an overt centring of the European experience. The tapestry of life and the human reshaping of environments evoke both concern and hope, making it vital to understand when, why, and how we came to this particular turn in the road. Eschewing easy labels and questioning eurocentrism in today’s climate vocabulary, this is a volume that will stimulate rethinking among scholars and citizens alike.


Sign in / Sign up

Export Citation Format

Share Document